Neu­ro­science biotech led by for­mer Pfiz­er crew wins $17M to tar­get tox­ic tau

With big phar­ma play­ers march­ing out of the dis­as­ter-prone field of neu­ro­sciences one-by-one, small biotechs are pick­ing up the tab.

Cam­bridge, Mass­a­chu­setts-based Pin­teon Ther­a­peu­tics is the lat­est ini­tia­tive. The com­pa­ny, found­ed in 2014, is de­vel­op­ing a tau an­ti­body to ad­dress an ar­ray of neu­rode­gen­er­a­tive dis­or­ders. On Thurs­day, it un­veiled $17 mil­lion in se­ries A fund­ing from Morn­ing­side Ven­tures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER